Drugs of Abuse Screen, DAU9, Urine
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Detecting drug abuse involving amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, tetrahydrocannabinol, methadone, and propoxyphene
This test is intended to be used only by a qualified drug treatment counselor or physician.
Reflex Tests Lists test(s) that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial test(s)
|Test ID||Reporting Name||Available Separately||Always Performed|
|MSOP||Drug of Abuse, Opiate Conf, U||No||No|
|DAUAM||Drug of Abuse, Amphetamine Conf, U||Yes||No|
|DAUBZ||Drug of Abuse, Benzo Conf, U||Yes||No|
|MSBR||Drug of Abuse, Barbiturate Conf, U||Yes||No|
|MSCO||Drug of Abuse, Cocaine Conf, U||Yes||No|
|MSMT||Drug of Abuse, Methadone Conf, U||Yes||No|
|MSPCP||Drug of Abuse, Phencyclidine Conf U||Yes||No|
|MSPR||Drug of Abuse, Propoxyphene Conf, U||Yes||No|
|MSTHC||Drug of Abuse, THC Conf, U||Yes||No|
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
If the cocaine screen is >149 ng/mL then cocaine confirmation is performed at an additional charge.
If the THC screen is >49 ng/mL then THC confirmation is performed at an additional charge.
If the opiate screen is >299 ng/mL then opiate confirmation is performed at an additional charge.
If the barbiturate screen is >199 ng/mL then barbiturate confirmation is performed at an additional charge.
If the benzodiazepine screen is >199 ng/mL then benzodiazepine confirmation is performed at an additional charge.
If the phencyclidine screen is >24 ng/mL then phencyclidine confirmation is performed at an additional charge.
If the amphetamines screen is >499 ng/mL then amphetamines confirmation is performed at an additional charge.
If the methadone screen is >299 ng/mL then methadone confirmation is performed at an additional charge.
If the propoxyphene screen is >299 ng/mL then propoxyphene confirmation is performed at an additional charge.
DAU9/505320: Enzyme-Multiplied Immunoassay Technique (EMIT)
MSCO/500369, MSTHC/500370, MSBR/500367, DAUBZ/500368, MSPCP/500371, DAUAM/500366, MSMT/500372, MSPR/500373: Gas Chromatography-Mass Spectrometry (GC-MS) (if appropriate)
MSOP/500365: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) (if appropriate)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Drug of Abuse, Clin, DAU9, U
Drugs of Abuse Screen 9, Urine
Drugs of Abuse Screen 9, Urine
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Container/Tube: Plastic, 60-mL urine container (Supply T313)
Specimen Volume: 30 mL
1. Collect a random urine specimen.
2. No preservative.
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
|Urine||Refrigerated (preferred)||14 days|
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
This test uses immunologic testing for drugs by class and screens for the presence of amphetamines, barbiturates, benzodiazepines, cocaine, metabolite, methadone, opiates, phencyclidine, propoxyphene, and tetrahydrocannabinol in urine. Positive immunologic results are confirmed by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
The specific drug identified will be reported.
EMIT cutoff concentrations
Amphetamines: 500 ng/mL
Barbiturates: 200 ng/mL
Benzodiazepines: 200 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Methadone: 300 ng/mL
Opiates: 300 ng/mL
Phencyclidine: 25 ng/mL
Propoxyphene: 300 ng/mL
THC: 50 ng/mL
Results of this test are confirmed and should be considered definitive. Specimens are normally kept for 2 weeks after Mayo Medical Laboratories New England receipt date.
A positive result indicates that the patient has used the drugs detected in the recent past.
For information about drug testing, including estimated detection times, see Drugs of Abuse Testing at http://www.mayomedicallaboratories.com/articles/drug-book/index.html
Creatinine and specific gravity are measured as indicators of specimen dilution.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
This immunologic testing technology exhibits a small (approximately 2%) false-positive rate due to the interaction of the reagents with naturally occurring substances and over-the-counter drugs.
This test does not screen or confirm for drug classes other than those listed above.
Note: Results are intended to be interpreted by a physician or health care professional. This test is not intended for use in employment-related testing.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
Porter WF, Moyer TP: Clinical toxicology. In Tietz Textbook of Clinical Chemistry. Fourth edition. Edited by CA Burtis, ER Ashwood. Philadelphia, WB Saunders Company, 1993, pp 1155-1235
Method Description Describes how the test is performed and provides a method-specific reference
Enzyme-multiplied immunoassay technique (EMIT). Positives confirmed by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS).(Unpublished Mayo methods)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Friday, Sunday
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
80104-Drug screen, multiple drug class method
G0431-Drug screen, multiple drug class method-government payers (if appropriate)
80154-Benzodiazepines (if appropriate)
80299-Propoxyphene (if appropriate)
80299-Tetrahydrocannabinol carboxylic acid (if appropriate)
82145-Amphetamines (if appropriate)
82205-Barbiturates (if appropriate)
82520-Cocaine (if appropriate)
83840-Methadone (if appropriate)
83925-Opiates (if appropriate)
83992-Phencyclidine (if appropriate)
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
|Result ID||Reporting Name||LOINC Code|